Administrative information
CHRONIC LIVER FAILURE, LIVER FIBROSIS, PORTAL HYPERTENSION
Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see 1366.0021 EudraCT No. 2021–001,285-38; ClinicalTrials NCT no. NCT051614811366.0029 EudraCT No. 2021–005,171-40; ClinicalTrials NCT no. NCT052821211366.0021: c34798591-06 (version 6.0, 14/12/2022)1366.0029: c36380139-04 (version 4.0, 15/12/2022)TR:1 Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria2 Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria3 Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, AustriaAB: Department for Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandJT:1 Department of Internal Medicine B, University of Münster, Münster, Germany2 European Foundation for the Study of Chronic Liver Failure, EFCLIF, Barcelona, SpainJE: Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GermanyIG: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyRS: Boehringer Ingelheim Ltd, Bracknell, UKAT: Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria1366.0021Ros SwallowBoehringer Ingelheim LtdBracknell, Berkshire, UKPhone: + 44 1344 742535Fax: + 44 1344 5854791366.0029Andrea TomisserBoehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5–11, A-1121 Wien, AustriaPhone: + 43 1 80 105–8286Fax: + 43 1 80 105–2375